CytomX Therapeutics, Inc. (CTMX) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2025
Loading P/E history...
CTMX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, CytomX Therapeutics, Inc. (CTMX) trades at a price-to-earnings ratio of -26.7x, with a stock price of $4.00 and trailing twelve-month earnings per share of $-0.33.
The current P/E is 139% below its 5-year average of 67.8x. Over the past five years, CTMX's P/E has ranged from a low of 1.3x to a high of 484.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CTMX trades at a 219% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CTMX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CTMX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CTMX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $369M | 11.9Lowest | -Best | -2%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CTMX Historical P/E Data (2023–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $4.26 | $0.01 | 484.1x | +614% |
| FY2025 Q3 | $3.19 | $0.42 | 7.6x | -89% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $2.27 | $0.58 | 3.9x | -94% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $0.64 | $0.50 | 1.3x | -98% |
| FY2024 Q4 | $1.03 | $0.40 | 2.6x | -96% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $1.18 | $0.17 | 6.8x | -90% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $1.22 | $0.14 | 8.6x | -87% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $2.18 | $0.20 | 10.7x | -84% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $1.55 | $0.02 | 84.2x | +24% |
Average P/E for displayed period: 67.8x
See CTMX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTMX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTMX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTMX — Frequently Asked Questions
Quick answers to the most common questions about buying CTMX stock.
Is CTMX stock overvalued or undervalued?
CTMX trades at -26.7x P/E, below its 5-year average of 67.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CTMX's valuation compare to peers?
CytomX Therapeutics, Inc. P/E of -26.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is CTMX's PEG ratio?
CTMX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2025.